Novartis said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat ...

The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, ...

The new drug, developed by Novartis and MMV, isn't a malaria vaccine, but can help treat babies with the disease.

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

Switzerland’s medical products authority has granted the first approval for a malaria medicine designed for small infants.

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

Malaria caused 597,000 deaths worldwide in 2023, with children under 5 accounting for 76 percent of all malaria deaths in the ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, ...

Swiss medicines regulator Swissmedic has approved Coartem Baby, a Novartis anti-malaria drug developed for infants weighing ...

Novartis has won approval in Switzerland for the world’s first malaria drug for newborns and infants, creating a new weapon ...

Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are ...